Positive final results in stroke
CLINUVEL today released positive final results of the open label pilot study...
Read MoreCLINUVEL Extends Employment Agreement With CEO
CLINUVEL today announced that it has extended the Employment Agreement with the...
Read MoreDNA Repair Communiqué II
In this DNA Repair Communiqué II we delve deeper into the topic...
Read MoreFirst XP-V Patient Treated in CLINUVEL DNA Repair Study
CLINUVEL today announced that the first disease-free subjects have received afamelanotide as...
Read MoreAfamelanotide in stroke (AIS) – positive preliminary results
CLINUVEL today released positive preliminary results from its pilot study (CUV801) in...
Read MoreDNA Repair Communiqué I
This first Communiqué in a series on DNA forms an introductory foundation,...
Read MoreCLINUVEL Expands DNA Repair Program with 2nd DNA Repair Study
CLINUVEL today announced that the first disease-free subjects have received afamelanotide as...
Read MoreSCENESSE® continued in Germany
CLINUVEL today announced that it has entered a second agreement with the...
Read MoreCLINUVEL completes enrolment in world-first stroke study
CLINUVEL today announced that it has completed enrolment in its world-first study...
Read MoreVitiligo Communiqué IV
CLINUVEL’s fourth Vitiligo Communiqué discusses the long-term consequences, both physical and psychological,...
Read MoreFirst Patient Treated in CLINUVEL DNA Repair Study
Melbourne, Australia, 22 October 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...
Read MoreCLINUVEL Progresses DNA Repair Program
Melbourne, Australia, 05 October 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...
Read MoreAfamelanotide well tolerated by first stroke patients
CLINUVEL’s drug afamelanotide was well tolerated by the first three arterial ischaemic...
Read MoreMedia Release - First stroke patient treated with afamelanotide
Melbourne, Australia, 07 June 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...
Read MoreMedia Release - CLINUVEL Expands DNA Repair Program
SCENESSE® (afamelanotide 16mg) to be evaluated in xeroderma pigmentosum variant (XP-V) CLINUVEL...
Read More